The status of rotigotine as a safe and effective alternative in the treatment of restless legs syndrome

References

• De Quincey T. Confessions of an English Opium-Eater and Suspira de Profundis. Boston : Ticknor, Reed, and Fields’ 1953.
   Google Scholar
• Miranda M, Williams AM, Garcia-Borreguero D. Thomas de Quincey and his restless legs symptoms as depicted in “Confessions of an English Opium-Eater”. Mov Disord. 2010;25(13):2006–2009.
   Web of Science ®Google Scholar
• Teive HA, Munhoz RP, Barbosa ER. Professor karl-axel ekbom and restless legs syndrome. Parkinsonism Relat Disord. 2009;15(4):254–257.
   PubMed Web of Science ®Google Scholar
• Ohayon MM, O’Hara R, Vitiello MV Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16(4):283–295.
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J; for Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health, International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101–119.
   Google Scholar
• Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286–1292.
   PubMedGoogle Scholar
• Balaban H, Bayrakli F, Kartal U, Pinarbasi E, Topaktas S, Kars HZ. A novel locus for restless legs syndrome on chromosome 13q. Eur Neurol. 2012;68(2):111–116.
   Web of Science ®Google Scholar
• Kemlink D, Plazzi G, Vetrugno R, et al. Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics. 2008;9(2):75–82.
   Web of Science ®Google Scholar
• Levchenko A, Provost S, Montplaisir JY, et al. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology. 2006;67(5):900–901.
   Web of Science ®Google Scholar
• Pichler I, Marroni F, Volpato CB, et al. Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet. 2006;79(4):716–723.
   Web of Science ®Google Scholar
• Sas AM, Di Fonzo A, Bakker SL, et al. Autosomal dominant restless legs syndrome maps to chromosome 20p13 (RLS-5) in a Dutch kindred. Mov Disord. 2010;25(11):1715–1722.
   Web of Science ®Google Scholar
• Skehan EB, Abdulrahim MM, Parfrey NA, Hand CK. A novel locus for restless legs syndrome maps to chromosome 19p in an Irish pedigree. Neurogenetics. 2012;13(2):125–132.
   Web of Science ®Google Scholar
• Winkelmann J, Muller-Myhsok B, Wittchen HU, et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol. 2002;52(3):297–302.
   Web of Science ®Google Scholar
• Winkelmann J, Czamara D, Schormair B, et al. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet 2011;7(7):e1002171.
   PubMed Web of Science ®Google Scholar
• Xiong L, Jang K, Montplaisir J, et al. Canadian restless legs syndrome twin study. Neurology. 2007;68(19):1631–1633.
   Web of Science ®Google Scholar
• Xiong L, Montplaisir J, Desautels A, et al. Family study of restless legs syndrome in Quebec, Canada: clinical characterization of 671 familial cases. Arch Neurol. 2010;67(5):617–622.
   PubMedGoogle Scholar
• Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011;26(1):114–120.
   PubMed Web of Science ®Google Scholar
• Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res. 2007;16(4):617–624.
   PubMed Web of Science ®Google Scholar
• Li Y, Mirzaei F, O’Reilly EJ, et al. Prospective study of restless legs syndrome and risk of depression in women. Am J Epidemiol. 2012;176(4):279–288.
   PubMed Web of Science ®Google Scholar
• Fulda S, Beitinger ME, Reppermund S, Winkelmann J, Wetter TC. Short-term attention and verbal fluency is decreased in restless legs syndrome patients. Mov Disord. 2010;25(15):2641–2648.
   PubMed Web of Science ®Google Scholar
• Gamaldo CE, Benbrook AR, Allen RP, Oguntimein O, Earley CJ. A further evaluation of the cognitive deficits associated with restless legs syndrome (RLS). Sleep Med. 2008;9(5):500–505.
   PubMed Web of Science ®Google Scholar
• Pearson VE, Allen RP, Dean T, Gamaldo CE, Lesage SR, Earley CJ. Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med. 2006;7(1):25–30.
   PubMed Web of Science ®Google Scholar
• Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome. Neurotherapeutics. 2012;9(4):776–790.
   Web of Science ®Google Scholar
• de Biase S, Merlino G, Lorenzut S, Valente M, Gigli GL. ADMET considerations for restless leg syndrome drug treatments. Expert Opin Drug Metab Toxicol. 2012;8(10):1247–1261.
   PubMed Web of Science ®Google Scholar
• Hornyak M, Trenkwalder C, Kohnen R, Scholz H. Efficacy and safety of dopamine agonists in restless legs syndrome. Sleep Med. 2012;13(3):228–236.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008;23(16):2267–2302.
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Kitsios GD, Papathanasiou AA, et al. Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. Clin Ther. 2010;32(2):221–237.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society, Eur J Neurol. 2012;19(11):1385–1396.
   Web of Science ®Google Scholar
• Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039–1062.
   PubMed Web of Science ®Google Scholar
• Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19(3):205–213.
   PubMed Web of Science ®Google Scholar
• García-Borreguero D, Allen RP, Kohnen R, et al; for International Restless Legs Syndrome Study Group. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007;8(5):520–530.
   PubMed Web of Science ®Google Scholar
• Reynolds NA, Wellington K, Easthope SE. Rotigotine: in Parkinson’s disease. CNSDrugs. 2005;19(11):973–981.
   Google Scholar
• Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol. 2003;60(12):1721–1728.
   PubMedGoogle Scholar
• Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012;34(4):966–978.
   PubMed Web of Science ®Google Scholar
• Cawello W, Wolff HM, Meuling WJ, Horstmann R, Braun M. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet. 2007;46(10):851–857.
   Web of Science ®Google Scholar
• Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos. 2009;37(10):2055–2060.
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272–276.
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH; for Rotigotine Sp 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord. 2004;19(12):1432–1438.
   Web of Science ®Google Scholar
• Oertel WH, Benes H, García-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010;ll(9):848–856.
   Google Scholar
• Trenkwalder C, Benes H, Poewe W, et al; for SP790 Study Group. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008;7(7):595–604.
   PubMed Web of Science ®Google Scholar
• Hening WA, Allen RP, Ondo WG, et al; for SP792 Study Group. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25(11):1675–1683.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al; for Rotigontine SP 709 Study Group. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebocontrolled, six-week dose-finding trial in Europe. Sleep Med. 2008;9(3):228–239.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al; for Rotigotine SP710 Study Group. One year open-label safety and efficacy trial with rotigo- tine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med. 2008;9(8):865–873.
   Web of Science ®Google Scholar
• Oertel W, Trenkwalder C, Benes H, et al; for SP710 Study Group. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10(8):710–720.
   PubMed Web of Science ®Google Scholar
• Dohin E, Högl B, Ferini-Strambi L, et al. Safety and efficacy of rotigo- tine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1–3 mg/24 h for up to 5 years. Expert Opin Pharmacother. 2013;14(1):15–25.
   Web of Science ®Google Scholar
• Hinnell C, Hulse N, Martin A, Samuel M. Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy. Parkinsonism Relat Disord. 2011;17(4):295–296.
   Web of Science ®Google Scholar
• Wingo TS, Evatt M, Scott B, Freeman A, Stacy M. Impulse control disorders arising in 3 patients treated with rotigotine. Clin Neuropharmacol. 2009;32(2):59–62.
   PubMed Web of Science ®Google Scholar
• Schreglmann SR, Gantenbein AR, Eisele G, Baumann CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18(2):207–209.
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ. Sleep attack associated to rotigotine. Clin Neuropharmacol. 2009;32(6):365.
   Web of Science ®Google Scholar
• Benes H, García-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012;13(6):589–597.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Hirata K, Hayashida K, Hattori N, Tomida T, Garcia-Borreguero D; for Rotigotine Study Group. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuropsychop- harmacol Biol Psychiatry. 2013;40:326–333.
   PubMed Web of Science ®Google Scholar
• Malik M, Andreas JO, Hnatkova K, et al. Thorough QT/QTc study in patients with advanced Parkinson’s disease: cardiac safety of rotigotine. Clin Pharmacol Ther. 2008;84(5):595–603.
   Web of Science ®Google Scholar
• Trotti LM, Bhadriraju S, Becker LA. Iron for restless legs syndrome. Cochrane Database Syst Rev. 2012;5:CD007834.
   Google Scholar
• Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW; for XP053 Study Group. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282–292.
   PubMed Web of Science ®Google Scholar
• Aurora RN, Kristo DA, Bista SR, et al. Update to the AASM Clinical Practice Guideline: “The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses”. Sleep. 2012;35(8):1037.
   Google Scholar